MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MYX - MAYNE PHARMA GROUP LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.39
Index: ASX300 | ALL-ORDS

Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$6.80

16 Apr
2024

-0.160

OPEN

$6.85

-2.30%

HIGH

$6.85

308,570

LOW

$6.60

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-385.1
DPS All xxxxxxxxxxxxxxx54.4
Sales/Revenue xxxxxxxxxxxxxxx183.6 M
Book Value Per Share xxxxxxxxxxxxxxx760.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-43.1 M
Net Profit Margin xxxxxxxxxxxxxxx-172.86 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-52.93 %
Return on Invested Capital xxxxxxxxxxxxxxx-51.27 %
Return on Assets xxxxxxxxxxxxxxx-24.88 %
Return on Equity xxxxxxxxxxxxxxx-52.93 %
Return on Total Capital xxxxxxxxxxxxxxx-22.56 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-96.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx14 M
Long Term Debt xxxxxxxxxxxxxxx33 M
Total Debt xxxxxxxxxxxxxxx48 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx229 M
Price To Book Value xxxxxxxxxxxxxxx0.58

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx219.6 M
Capex % of Sales xxxxxxxxxxxxxxx119.61 %
Cost of Goods Sold xxxxxxxxxxxxxxx157 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx213 M
Research & Development xxxxxxxxxxxxxxx16 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

MYX STOCK CHART